758 related articles for article (PubMed ID: 6221496)
1. Reversible inhibition of sperm production and gonadotrophin secretion in men following combined oral medroxyprogesterone acetate and percutaneous testosterone treatment.
Soufir JC; Jouannet P; Marson J; Soumah A
Acta Endocrinol (Copenh); 1983 Apr; 102(4):625-32. PubMed ID: 6221496
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of spermatogenesis in men using various combinations of oral progestagens and percutaneous or oral androgens.
Guerin JF; Rollet J
Int J Androl; 1988 Jun; 11(3):187-99. PubMed ID: 2970439
[TBL] [Abstract][Full Text] [Related]
3. The combined use of oral medroxyprogesterone acetate and methyltestosterone in a male contraceptive trial programme.
Bain J; Rachlis V; Robert E; Khait Z
Contraception; 1980 Apr; 21(4):365-79. PubMed ID: 6771093
[TBL] [Abstract][Full Text] [Related]
4. Reversible azoospermia induced by an androgen-progestin combination regimen in Indonesian men.
Pangkahila W
Int J Androl; 1991 Aug; 14(4):248-56. PubMed ID: 1831798
[TBL] [Abstract][Full Text] [Related]
5. Combination of 19-nortestosterone-hexyloxyphenylpropionate (Anadur) and depot-medroxyprogesterone-acetate (Clinovir) for male contraception.
Knuth UA; Yeung CH; Nieschlag E
Fertil Steril; 1989 Jun; 51(6):1011-8. PubMed ID: 2524404
[TBL] [Abstract][Full Text] [Related]
6. Establishing the minimum effective dose and additive effects of depot progestin in suppression of human spermatogenesis by a testosterone depot.
Handelsman DJ; Conway AJ; Howe CJ; Turner L; Mackey MA
J Clin Endocrinol Metab; 1996 Nov; 81(11):4113-21. PubMed ID: 8923869
[TBL] [Abstract][Full Text] [Related]
7. Use of low-dosage oral cyproterone acetate as a male contraceptive.
Wang C; Yeung KK
Contraception; 1980 Mar; 21(3):245-72. PubMed ID: 6771091
[TBL] [Abstract][Full Text] [Related]
8. Spermatogenesis in men treated with injections of medroxyprogesterone acetate combined with testosterone enanthate.
Frick J; Danner C; Kunit G; Joos H; Köhle R
Int J Androl; 1982 Jun; 5(3):246-52. PubMed ID: 7118265
[TBL] [Abstract][Full Text] [Related]
9. Medium dose cyproterone acetate (CPA): effects on hormone secretion and on spermatogenesis in men.
Moltz L; Römmler A; Post K; Schwartz U; Hammerstein J
Contraception; 1980 Apr; 21(4):393-413. PubMed ID: 6771095
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of long-term treatment with levo-norgestrel and testosterone enanthate in normal men.
Foegh M; Nicol K; Petersen IB; Schou G
Contraception; 1980 Jun; 21(6):631-40. PubMed ID: 6775869
[TBL] [Abstract][Full Text] [Related]
11. Radioimmunoassays of ethinyl-norgestrienone (R-2323) and medroxyprogesterone acetate (MPA) and their clinical applicability.
Frick J; Bartsch G; Jakse G
Urol Res; 1977; 5(2):55-9. PubMed ID: 69351
[TBL] [Abstract][Full Text] [Related]
12. Pregnancies associated with sperm concentrations below 10 million/ml in clinical studies of a potential male contraceptive method, monthly depot medroxyprogesterone acetate and testosterone esters.
Barfield A; Melo J; Coutinho E; Alvarez-Sanchez F; Faundes A; Brache V; Leon P; Frick J; Bartsch G; Weiske WH; Brenner P; Mishell D; Bernstein G; Ortiz A
Contraception; 1979 Aug; 20(2):121-7. PubMed ID: 487815
[TBL] [Abstract][Full Text] [Related]
13. Study of medroxyprogesterone acetate and testosterone enanthate as a male contraceptive.
Brenner PF; Mishell DR; Bernstein GS; Ortiz A
Contraception; 1977 Jun; 15(6):679-91. PubMed ID: 891194
[TBL] [Abstract][Full Text] [Related]
14. Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. I: Plasma luteinizing hormone, follicle stimulating hormone, testosterone, estradiol, and inhibin concentrations.
Wallace EM; Gow SM; Wu FC
J Clin Endocrinol Metab; 1993 Jul; 77(1):290-3. PubMed ID: 8325955
[TBL] [Abstract][Full Text] [Related]
15. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production.
Matsumoto AM
J Clin Endocrinol Metab; 1990 Jan; 70(1):282-7. PubMed ID: 2104626
[TBL] [Abstract][Full Text] [Related]
16. The influence of pharmaceutical compounds on male fertility.
Neumann F; Diallo FA; Hasan SH; Schenck B; Traore I
Andrologia; 1976; 8(3):203-35. PubMed ID: 793446
[TBL] [Abstract][Full Text] [Related]
17. Serum follicle-stimulating hormone, luteinizing hormone and progesterone concentrations in pseudopregnant rats treated with medroxyprogesterone acetate.
de Greef WJ; Dullaart J; Zeilmaker GH
J Endocrinol; 1976 Sep; 70(3):465-71. PubMed ID: 978105
[TBL] [Abstract][Full Text] [Related]
18. Combined administration of levonorgestrel and testosterone induces more rapid and effective suppression of spermatogenesis than testosterone alone: a promising male contraceptive approach.
Bebb RA; Anawalt BD; Christensen RB; Paulsen CA; Bremner WJ; Matsumoto AM
J Clin Endocrinol Metab; 1996 Feb; 81(2):757-62. PubMed ID: 8636300
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of ovulation during discontinuous intranasal luteinizing hormone-releasing hormone agonist dosing in combination with gestagen-induced bleeding.
Lemay A; Faure N; Labrie F; Fazekas AT
Fertil Steril; 1985 Jun; 43(6):868-77. PubMed ID: 3158551
[TBL] [Abstract][Full Text] [Related]
20. Administration of norethandrolone and testosterone as a contraceptive agent for men.
Brenner PF; Bernstein GS; Roy S; Jecht EW; Mishell DR
Contraception; 1975 Feb; 11(2):193-207. PubMed ID: 1112088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
